share_log

Shanghai MicroPort EP MedTech (SHSE:688351) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Shanghai MicroPort EP MedTech (SHSE:688351) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

上海微創醫療(SHSE:688351)發佈了健康的收益,但還有一些其他因素需要注意
Simply Wall St ·  08/28 19:07

Shanghai MicroPort EP MedTech Co., Ltd. (SHSE:688351) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.

上海微創醫療有限公司(SHSE:688351)宣佈盈利強勁,但股票一直處於停滯狀態。我們的分析表明,這可能是因爲股東注意到了一些值得關注的潛在因素。

1724886420888
SHSE:688351 Earnings and Revenue History August 28th 2024
SHSE:688351的盈利和營業收入歷史記錄爲2024年8月28日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

To properly understand Shanghai MicroPort EP MedTech's profit results, we need to consider the CN¥24m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Shanghai MicroPort EP MedTech's positive unusual items were quite significant relative to its profit in the year to June 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

要正確理解上海微創醫療有限公司的盈利結果,我們需要考慮到2400萬元人民幣的非常規項目收益。我們不能否認,更高的利潤通常使我們保持樂觀,但我們希望這種利潤能夠持續。當我們分析了全球絕大多數上市公司時,我們發現重大的非常規項目通常不會重複出現。這符合我們的預期,因爲這些增益被描述爲「非常規」。我們可以看到,相對於2024年6月的利潤而言,上海微創醫療的正面非常規項目相當重要。因此,我們可以推斷出這些非常規項目使其法定利潤比原本強勁得多。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Shanghai MicroPort EP MedTech's Profit Performance

我們對上海微創醫療有限公司的盈利表現看法

As we discussed above, we think the significant positive unusual item makes Shanghai MicroPort EP MedTech's earnings a poor guide to its underlying profitability. For this reason, we think that Shanghai MicroPort EP MedTech's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The silver lining is that its EPS growth over the last year has been really wonderful, even if it's not a perfect measure. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Shanghai MicroPort EP MedTech as a business, it's important to be aware of any risks it's facing. In terms of investment risks, we've identified 1 warning sign with Shanghai MicroPort EP MedTech, and understanding this should be part of your investment process.

正如我們上面所討論的,我們認爲顯著的正常外部項目使得上海微創醫療的收益成爲了其基本盈利能力的一個不良指標。由於這個原因,我們認爲上海微創醫療公司的業績可能不是其基本盈利能力的一個好指標,並且可能會給投資者帶來過於積極的印象。其中一絲曙光是它在過去一年的每股收益增長非常出色,即使它不是一個完美的指標。當然,在分析其盈利方面,我們只是探索了皮毛;人們還可以考慮利潤率、預測增長和投資回報率等其他因素。如果您想了解上海微創醫療業務的更多信息,了解其所面臨的風險是非常重要的。在投資風險方面,我們已經發現上海微創醫療公司有1個警告信號,理解這一點應該是您投資過程中的一部分。

Today we've zoomed in on a single data point to better understand the nature of Shanghai MicroPort EP MedTech's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天,我們聚焦在一個單一的數據點上,以更好地了解上海微創醫療的利潤性質。但是,如果您能集中注意力在細枝末節上,您還可以發現更多。有些人認爲高淨資產回報率是一個高質量企業的良好標誌。所以您可能希望查看這個免費的高淨資產回報率企業集合,或者這個高內部持股比例的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論